PVCT Provectus Pharmaceutical Inc
Provectus Pharmaceutical Inc (PVCT) is expected to report earnings on November 12, 2026, after the market close.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Provectus Pharmaceutical Inc
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.
Sector
Healthcare